NASDAQ:SYBXSynlogic Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synlogic Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.40 +0.04 (+1.69 %) (As of 08/13/2020 09:36 AM ET) Add Compare Share Today's Range$2.37Now: $2.40▼$2.6050-Day Range$1.85MA: $2.13▼$2.4052-Week Range$1.35Now: $2.40▼$5.25Volume489,500 shsAverage Volume365,989 shsMarket Capitalization$82.00 millionP/E RatioN/ADividend YieldN/ABeta2.23 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingSynlogic has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, Synlogic has a potential upside of 205.6% from its current price of $2.40.Amount of Analyst CoverageSynlogic has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesSynlogic has received 292 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSynlogic has received 248 “underperform” votes. (Add your “underperform” vote.)Community SentimentSynlogic has received 54.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote “Outperform” if you believe SYBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSynlogic does not currently pay a dividend.Dividend GrowthSynlogic does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synlogic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 17.95% of the stock of Synlogic is held by insiders.Percentage Held by Institutions49.62% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Synlogic are expected to grow in the coming year, from ($1.84) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Synlogic is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synlogic is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynlogic has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYBX Previous Symbol CUSIPN/A CIK1527599 Webwww.synlogictx.com Phone617-401-9975Debt Debt-to-Equity Ratio0.16 Current Ratio18.68 Quick Ratio18.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.22 million Price / Sales36.94 Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book0.49Profitability EPS (Most Recent Fiscal Year)($1.70) Net Income$-51,370,000.00 Net Margins-2,761.83% Return on Equity-36.85% Return on Assets-30.66%Miscellaneous Employees74 Outstanding Shares34,166,000Market Cap$82.00 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $2.40 +0.04 (+1.69 %) (As of 08/13/2020 09:36 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SYBX News and Ratings via Email Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Synlogic (NASDAQ:SYBX) Frequently Asked Questions How has Synlogic's stock price been impacted by COVID-19 (Coronavirus)? Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYBX stock has increased by 55.8% and is now trading at $2.40. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Synlogic? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Synlogic. When is Synlogic's next earnings date? Synlogic is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Synlogic. How were Synlogic's earnings last quarter? Synlogic Inc (NASDAQ:SYBX) released its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. Synlogic had a negative return on equity of 36.85% and a negative net margin of 2,761.83%. View Synlogic's earnings history. When did Synlogic's stock split? How did Synlogic's stock split work? Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split. What price target have analysts set for SYBX? 5 Wall Street analysts have issued 1 year target prices for Synlogic's stock. Their forecasts range from $2.00 to $13.00. On average, they expect Synlogic's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 205.6% from the stock's current price. View analysts' price targets for Synlogic. Has Synlogic been receiving favorable news coverage? News articles about SYBX stock have trended extremely negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Synlogic earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about Synlogic. Are investors shorting Synlogic? Synlogic saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 353,100 shares, an increase of 7.2% from the July 15th total of 329,400 shares. Based on an average daily volume of 338,600 shares, the short-interest ratio is presently 1.0 days. Currently, 1.9% of the shares of the stock are sold short. View Synlogic's Short Interest. Who are some of Synlogic's key competitors? Some companies that are related to Synlogic include CytomX Therapeutics (CTMX), Geron (GERN), REDHILL BIOPHAR/S (RDHL), Pivot Pharmaceuticals (PVOTF), Aeglea Bio Therapeutics (AGLE), MEI Pharma (MEIP), Immunic (IMUX), Concert Pharmaceuticals (CNCE), OptiNose (OPTN), Arbutus Biopharma (ABUS), Tiziana Life Sciences (TLSA), Avadel Pharmaceuticals (AVDL), Affimed (AFMD), Osmotica Pharmaceuticals (OSMT) and Bicycle Therapeutics (BCYC). View all competitors. What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Verastem (VSTM) and Rigel Pharmaceuticals (RIGL). Who are Synlogic's key executives? Synlogic's management team includes the following people: Dr. Peter Barrett, Exec. Chairman (Age 66)Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)Prof. Timothy K. Lu, Co-FounderDr. James J. Collins, Co-Founder What is Synlogic's stock symbol? Synlogic trades on the NASDAQ under the ticker symbol "SYBX." Who are Synlogic's major shareholders? Synlogic's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.25%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View institutional ownership trends for Synlogic. Which major investors are selling Synlogic stock? SYBX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. View insider buying and selling activity for Synlogic. Which major investors are buying Synlogic stock? SYBX stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View insider buying and selling activity for Synlogic. How do I buy shares of Synlogic? Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Synlogic's stock price today? One share of SYBX stock can currently be purchased for approximately $2.40. How big of a company is Synlogic? Synlogic has a market capitalization of $82.00 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe. What is Synlogic's official website? The official website for Synlogic is www.synlogictx.com. How can I contact Synlogic? Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
